Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

fter, and follow any dose adjustments. - Sudden deaths have been reported in patients receiving nilotinib. Do not administer TASIGNA to patients with hypokalemia, hypomagnesemia, or long QT syndrome. - Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.- Patients should avoid food 2 hours before and 1 hour after taking dose.
  • Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia, and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months and then monthly thereafter.
  • Caution is recommended in patients with a history of pancreatitis.
  • The use of TASIGNA may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase.
  • TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia (see Boxed WARNING).
  • The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (including, but not limited to, amiodarone, disopyramide, procainamide, quinidine, and sotalol) and other drugs that may prolong the QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, and pimozide) should be avoided. Grapefruit products should also be avoided. 
  • The concomitant use of strong CYP3A4 inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St. John's wort).
  • TASIGNA must not be taken with food.
  • TASIGNA exposure is increased in patients with impaired hepatic function.
  • Cases of tumor lysis syndrome have been reported in TASIGNA treated patients with resistant or intolerant CML. Due to potential for tumor lysis syndrome, maintain adequate hydration and correct uric acid levels prior to initiating therapy with TASIGNA.
  • The exposure of TASIGNA is reduced in patients with total gastrectomy.
  • Since the capsules contain lactose, TASIGNA is not recommended for p
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... MA (PRWEB) September 30, 2014 ... SoundConnect announces four new-hosted collaboration bundles ... bundles deliver high quality conferencing experiences for low, ... packages to choose from, businesses have optimized solutions ... bundled solutions include audio only minutes (1K, ...
    (Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
    (Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
    (Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
    Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
    ... 4, 2011 The ALS Therapy Development ... Godhwani, a successful Silicon Valley entrepreneur, to its board ... organization with a mission to discover and develop treatments ... Lou Gehrig,s Disease). (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO ) ...
    ... LAS VEGAS, Feb. 4, 2011 Cord Blood America, ... CBAI ), the umbilical cord blood stem cell preservation ... stem cells to families nationwide and internationally, announced today that ... and international cell and tissue bank to provide placenta, umbilical ...
    ... Codexis, Inc. (Nasdaq: CDXS ) today announced ... December 31, 2010.   Full Year ... driven by a 77% increase in sales of pharmaceutical ... in 2010, and increases in collaborative R&D and government ...
    Cached Biology Technology:ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors 2Cord Blood America Announces Second Supply Agreement to Provide Placenta, Umbilical Cord Collection Services to Major Tissue Bank 2Codexis Reports Fourth Quarter and Full Year 2010 Results 2Codexis Reports Fourth Quarter and Full Year 2010 Results 3Codexis Reports Fourth Quarter and Full Year 2010 Results 4Codexis Reports Fourth Quarter and Full Year 2010 Results 5Codexis Reports Fourth Quarter and Full Year 2010 Results 6Codexis Reports Fourth Quarter and Full Year 2010 Results 7Codexis Reports Fourth Quarter and Full Year 2010 Results 8
    (Date:10/1/2014)... TURKU , Finnland, October 1, 2014 ... der Durchbruch im Bereich der Biowissenschaften   ... Jahren ein Kommen und Gehen zahlreicher Detektionstechnologien. ... sich zum goldenen Standard. Die Photonen-Upconversion ist ... den letzten Jahren mit Begeisterung aufgenommen wurde. ...
    (Date:9/30/2014)... at the University of California, San Diego, have completed ... using a method that uses the pixels in an ... known as mesh-free simulation. , The researchers, led by ... at the Jacobs School of Engineering at UC San ... method at the CompIMAGE,14 conference in Pittsburgh this month. ...
    (Date:9/30/2014)... Institutes of Health (NIH) awarded Lawrence Livermore National ... electrode array system that will enable researchers to ... resolution and scale. , LLNL,s grant-funded project is ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... our understanding of the human mind and uncover ...
    Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
    ... time in its history, the American Society for Cell Biology ... the ASCB,s Annual Meeting, for "An Evening of Art & ... Dec. 15. Members of the public who sign ... complimentary registration to the ASCB keynote addresses by Stephen Chu, ...
    ... into a previously unknown structure in between a liquid ... containing long oily chains, according to Purdue University researchers. ... Water plays a huge role in biological processes, ... be that this transformation is useful in a way ...
    ... Missouri researcher Mark Flinn, professor of anthropology, has been ... of Science fellow for his "theoretical contributions in the ... pioneering field research on stress response, family environment, and ... Election as a fellow of the AAAS ...
    Cached Biology News:Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2Oil and water: An icy interaction when oil chains are short, but steamy when chains are long 2Oil and water: An icy interaction when oil chains are short, but steamy when chains are long 3Cultural anthropologist Mark Flinn named 2013 AAAS Fellow 2
    ... Free Epitope Design consultation. Peptide synthesis ... amino acids). Conjugation to KLH. ... Immunization of 2 New Zealand white female ... immunizations and 4 production bleeds. Elisa ...
    Request Info...
    ... 5 barrel liners, 5 white cartridge holders, cartridge ... gene gun is a convenient, hand-held device that ... range of targets in vivo. The unit uses ... or RNA-coated gold microcarriers from the inner wall ...
    Intestinal Epithelium Differentiation Environment...
    Biology Products: